复方香薷水治疗流感及流感样病例合并胃肠道症状有效性及安全性的临床评价  

Clinical Evaluation of Efficacy and Safety of Fufang Xiangru Shui in the Treatment of Influenza and Influenza-Like Cases Complicated with Gastrointestinal Symptoms

作　　者：刘妙辉 黄忠毅 LIU Miao-hui;HUANG Zhong-yi(Xiangjiang Community Health Service Center,Maluan Subdistrict,Pingshan District,Shenzhen 518118,China;Shenzhen Hospital of Southern Medical University,Shenzhen 518000,China)

机构地区：[1]深圳市坪山区马峦街道香江社区健康服务中心,深圳518118 [2]南方医科大学深圳医院,深圳518000

出　　处：《中国合理用药探索》2025年第3期118-125,共8页Chinese Journal of Rational Drug Use

摘　　要：目的:评估复方香薷水治疗流感及流感样病例合并胃肠道症状的有效性及安全性。方法:选取2023年6月~2024年8月期间某社区健康服务中心收治的240例流感及流感样病例合并胃肠道症状患者作为研究对象,采用随机数字表法分为对照组(失访脱落1例,n=119)和观察组(失访脱落1例,n=119)。对照组患者口服藿香正气口服液治疗,观察组患者口服复方香薷水治疗,两组均连续用药5天。比较两组患者临床痊愈时间、完全退热时间、中医证候积分、中医证候疗效、并发症发生率、合并用药情况及治疗安全性,并对单用藿香正气口服液及复方香薷水的患者进行亚组分析。结果:治疗后,观察组患者平均痊愈时间和平均完全退热时间均短于对照组(P<0.001)。两组患者各项主症积分及各项次症积分均降低(P<0.05),且观察组在发热、咳嗽、困倦方面的改善效果更优(P<0.05)。观察组患者临床痊愈率(74.79%)高于对照组(63.87%,P<0.05)。两组均未发生并发症。两组患者不良事件总发生率比较无统计学差异(P=0.06),且均未发生严重不良事件。两组患者合并用药总体占比及各合并用药情况比较均无统计学差异(P>0.05)。亚组分析结果显示,单用复方香薷水亚组较单用藿香正气口服液亚组在平均痊愈时间、平均完全退热时间以及中医证候积分改善情况方面均具有显著优势。结论:复方香薷水可有效缓解流感及流感样病例合并胃肠道症状患者的临床症状,治疗效果更佳,且安全性良好。Objective:To evaluate the efficacy and safety of Fufang Xiangru Shui in the treatment of influenza and influenza-like cases complicated with gastrointestinal symptoms.Methods:A total of 240 influenza and influenza-like patients complicated with gastrointestinal symptoms treated in a community health service center from June 2023 to August 2024 were selected and assigned to the control group(1 loss to follow-up,n=119)and the observation group(1 loss to follow-up,n=119)by random number table method.The control group was treated with Huoxiang Zhengqi oral liquid,and the observation group was treated with Fufang Xiangru Shui.Both groups were treated continuously for 5 days.The time to clinical recovery,time to complete defervescence,traditional Chinese medicine(TCM)symptom score,TCM syndrome efficacy,incidence of complications,concomitant medication and treatment safety were compared between the two groups,and subgroup analysis was conducted for the patients using Huoxiang Zhengqi oral liquid and Fufang Xiangru Shui alone.Results:After treatment,the average time to recovery and average time to complete defervescence in the observation group were shorter than those in the control group(P<0.001).The scores for primary symptoms and secondary symptoms were decreased in both groups(P<0.05),and the observation group showed superior improvement in fever,cough and lethargy compared to the control group(P<0.05).The clinical recovery rate of observation group(74.79%)was higher than that of control group(63.87%,P<0.05).There were no complications observed in both groups.There was no statistically significant difference in the total incidence of adverse events between the two groups(P=0.06),and no serious adverse events occurred in either group.There was no statistically significant difference in the overall proportion of concomitant medications and the comparison of each concomitant medication between the two groups(P>0.05).The subgroup analysis showed that the subgroup receiving Fufang Xiangru Shui alone was superior to the su

关 键 词：复方香薷水 流感 流感样病例 胃肠道症状 藿香正气口服液 

分 类 号：R511.7[医药卫生—内科学]